Collecting blood and urine samples for research on cardiovascular health
Official title: Obtaining Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research
Run by National Institutes of Health Clinical Center (CC) · NCT03253705 · Data updated 2026-11-12
This study is collecting blood and urine samples from healthy people and patients to see how certain biological markers relate to heart health and inflammation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | September 14, 2017 |
| Main results expected | August 1, 2037 |
| Study ends | August 1, 2037 |
| Registry record updated | October 23, 2026 |
| Trial ID | NCT03253705 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include healthy volunteers and patients aged 18 and older with cardiovascular conditions or inflammation.
✕Probably not a fit
Patients with severe anemia or those currently receiving high doses of certain medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect blood and urine samples from healthy volunteers and patients to analyze gene expression, proteins, metabolites, and other biological markers related to cardiovascular health and inflammation. Participants will undergo a brief initial visit for a history and physical exam, followed by routine blood and urine tests. The samples will be used to develop laboratory assays and protocols that can further research into conditions like pulmonary hypertension and arteriosclerosis.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment of cardiovascular diseases and related inflammatory conditions.
How similar studies have gone: Other studies focusing on blood and urine sample analysis for cardiovascular research have shown promise, indicating that this approach is supported by previous findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA FOR RESEARCH SUBJECTS WITH DISEASES RELATED TO CARDIOVASCULAR SYSTEM AND/OR INFLAMMATION AND/OR ENDOTHELIAL DYSFUNCTION SUCH AS BUT NOT LIMITED TO ARTERIOSCLEROSIS, TRANSPLANTATION, PULMONARY HYPERTENSION, OTHER ADVANCED LUNG OR HEART DISEASE 1. Males or females of age greater than or equal to 18 years old. 2. Subjects unable to provide informed consent must have a surrogate decision maker or another legally authorized representative (such as a legal guardian or holder of the DPA) EXCLUSION CRITERIA FOR RESEARCH SUBJECTS WITH DISEASES RELATED TO CARDIOVASCULAR SYSTEM AND/OR INFLAMMATION AND/OR ENDOTHELIAL DYSFUNCTION SUCH AS BUT NOT LIMITED TO ARTERIOSCLEROSIS, TRANSPLANTATION, PULMONARY HYPERTENSION, OTHER ADVANCED LUNG OR HEART DISEASE 1. Hemoglobin \<7.0 g/dL 2. Currently receiving infusion of epinephrine; or dopamine at an infusion rate of \>2.5 microgram/kg/min, norepinephrine of \> 20mcg/min, or vasopressin \> 0.04 units/min\* 3. In the presence of known coronary artery disease (CAD) a systolic blood pressure (SBP) \<90 mmHg. In the absence of known CAD a SBP \<80 mmHg or mean arterial pressure (MAP) \<60 mmHg with or without vasopressors\*. * For critically ill patients with shock (on vasopressors), no more than 20mL of blood may be obtained within a 24 hour period. (No more than 200ml over eight weeks.) Research subjects may be excluded if in the opinion of the study investigators they have a condition that may adversely affect the outcome of the study or the safety of the volunteer. INCLUSION CRITERIA FOR SUBJECTS WHO ARE TO RECEIVE CRRT (IRRESPECTIVE OF DIAGNOSIS) IN WHOM THE TOTAL AMOUNT OF PROTOCOL RELATED BLOOD WILL NOT EXCEED 8 ML. 1. Males or females of age greater than or equal to 18 years old. 2. Subjects unable to provide informed consent must have a surrogate decision maker or another legally authorized representative (such as a legal guardian or holder of the DPA) EXCLUSION CRITERIA FOR SUBJECTS WHO ARE TO RECEIVE CRRT (IRRESPECTIVE OF DIAGNOSIS) IN WHOM THE TOTAL AMOUNT OF PROTOCOL RELATED BLOOD WILL NOT EXCEED 8 ML) 1. Hemoglobin \<7.0 g/dL 2. In the presence of known coronary artery disease (CAD) a systolic blood pressure (SBP) \<90 mmHg. In the absence of known CAD a SBP \<80 mmHg or mean arterial pressure (MAP) \<60 mmHg. INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS: 1. Males or females of age greater than or equal to 18 years old 2. Ability of subjects to understand and the willingness to sign an informed consent document. EXCLUSION CRITERIA FOR HEATLHY VOLUNTEERS: 1. Blood or platelet donation within the last 6 weeks. 2. Hemoglobin below normal (e.g. below 11.2 g/dl for females and below 13.7 mg/dl for males at the NIH CC); subjects may return for evaluation at a later date. (After initial enrollment, hematocrit does not need to be done prior to subsequent blood draws unless there is interval development of symptomatic anemia) 3. History of recreational drug use with the exception of marijuana (as long as marijuana use was \>3 months from the time of study screening). 4. Active acute illness (i.e viral syndrome). Subjects may return for evaluation at a later date once the acute illness resolves. 5. Volunteers may be excluded if in the opinion of the study investigators they have a condition that may adversely affect the outcome of the study or the safety of the volunteer, such as, active tobacco use (\> 6 months) in the past ten years, any tobacco use within 3 months prior to the screening evaluation, a history of clinically relevant and active cardiopulmonary disease (e.g. Including but not limited to any cardiopulmonary diseases not well controlled by medications, EKG with evidence of clinically relevant heart disease, COPD with hypoxemia and forced expiratory volume/forced vital capacity (FEV1/FVC) \> 2 standard deviations from normal, etc.).
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Michael A Solomon, M.D. — National Institutes of Health Clinical Center (CC)
- Study coordinator: Grace M Graninger, R.N.
- Email: ggraninger@cc.nih.gov
- Phone: (301) 496-9320
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Endothelial extracellular vesicles in kids with newly diagnosed high blood pressure
This study tests whether levels of endothelial extracellular vesicles are different in children with new, untreated primary hypertension compared to normotensive children.
-
TB-500 (thymosin beta 4 fragment) to improve blood vessel function in people with stable atherosclerotic cardiovascular disease
This trial will test whether TB-500 (a fragment of thymosin beta 4) is safe and can improve blood vessel function in adults aged 40–75 with stable ASCVD.
-
Statin effects on hormones and erectile function in middle-aged men
This will test whether different doses of pitavastatin or rosuvastatin change sex hormone levels and improve erectile function in sexually active men aged 40-65 with high cardiovascular risk.
-
Effect of pre-surgery (neoadjuvant) therapy on surgical outcomes in colorectal cancer
We will test whether pre-surgery (neoadjuvant) therapy changes tiny blood vessels, increases tissue scarring, and raises the risk of wound and other perioperative complications in adults having colorectal cancer surgery.
-
How Lipoprotein(a) affects artery stiffness, blood vessel lining, and heart muscle movement
This project will see if higher Lipoprotein(a) levels are linked to stiffer arteries, worse endothelial function, and changes in left atrial and left ventricular motion in adults 18–75.
-
Testosterone and blood vessel health after spinal cord injury
This research tests if low testosterone in men with recent motor-complete paraplegia is linked to poorer blood vessel function and higher blood markers of endothelial injury.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.